No abstract

An unknown impurity in lansoprazole (2-[[[3-methyl-4-(2, 2, 2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole) was detected by HPLC and was identified as des-(trifluoroethoxy) lansoprazole, an principal synthetic route indicative impurity of lansoprazole. Lansoprazole was subjected to different ICH prescribed stress conditions like hydrolysis, oxidation, photolysis and thermal degradation conditions to enrich the impurity. The impurity was enriched by using acid catalytic degradation, isolated by using preparative HPLC and characterized (FTIR, MS and NMR). Limit of Detection (LOD) and Limit of Quantification (LOQ) are found to be 0.014% and 0.035% respectively.

During the process development of eletriptan hydrobromide, we have observed formation of an unknown impurity in the final product at enhanced levels which was identified as a methoxy substituted derivative on the side chain of the product. The present work involves detailed optimization studies directed toward the development of an efficient process for the commercial production of eletriptan hydrobromide substantially free from the methoxy impurity and other impurities.

No abstract

Aminothiazoles. Part 1. Syntheses and Pharmacological Evaluation of 4-[Isobutylphenyl]-2-substituted-aminothiazoles. -Four substituted thiazoles (V) are prepared and pharmacologically evaluated. (Vb) and (Vd) show anti-inflammatory activity, (Vd) also exhibits significant antibacterial activity against Bacillus subtilis, (Va), (Vc), and (Vd) show cardiotonic activity. -(GIRIDHAR, T.; REDDY, R. B.; PRASANNA, B.; MOULI, G. V. P.